Literature DB >> 2901042

Calcitonin gene-related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat.

H Kawasaki1, K Takasaki, A Saito, K Goto.   

Abstract

Systemic blood pressure is controlled by changes in the resistance of the peripheral vascular bed for example in the mesenteric blood vessels. The tone of peripheral blood vessels is primarily maintained by sympathetic vasoconstrictor nerves. Although vasodilator innervation has been identified in certain isolated elastic arteries, it is not known whether vasodilator nerves contribute to the regulation of the peripheral resistance vessels. We present pharmacological evidence for the existence of nonadrenergic, noncholinergic (NANC) vasodilator nerves in the mesenteric resistance vessel of the rat and that the resistance is controlled by not only sympathetic vasoconstrictor nerves but also NANC vasodilator nerves. We also show that the neurogenic vasodilation was selectively abolished by depleting endogenous calcitonin gene-related peptide (CGRP), a potent vasodilator neuropeptide, from perivascular nerves. This indicates that CGRP is a novel vasodilator neurotransmitter and may play a role in control of the total peripheral resistance of systemic circulation through a local reflex mechanism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901042     DOI: 10.1038/335164a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  99 in total

1.  Intrathecal injection of TRPV1 shRNA leads to increases in blood pressure in rats.

Authors:  S-Q Yu; D H Wang
Journal:  Acta Physiol (Oxf)       Date:  2011-04-22       Impact factor: 6.311

2.  Flow-induced release of adenosine 5'-triphosphate from endothelial cells of the rat mesenteric arterial bed.

Authors:  V Ralevic; P Milner; K A Kirkpatrick; G Burnstock
Journal:  Experientia       Date:  1992-01-15

3.  Effect of endothelium removal on the vasoconstrictor response to neuronally released 5-hydroxytryptamine and noradrenaline in the rat isolated mesenteric and femoral arteries.

Authors:  M Urabe; H Kawasaki; K Takasaki
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

4.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

5.  Alpha3beta4-nicotinic receptors mediate adrenergic nerve- and peptidergic (CGRP) nerve-dependent vasodilation induced by nicotine in rat mesenteric arteries.

Authors:  S Eguchi; S Miyashita; Y Kitamura; H Kawasaki
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

6.  Impaired sensory-motor nerve function in the isolated mesenteric arterial bed of streptozotocin-diabetic and ganglioside-treated streptozotocin-diabetic rats.

Authors:  V Ralevic; A Belai; G Burnstock
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

7.  Electrophysiological effects of activating the peptidergic primary afferent innervation of rat mesenteric arteries.

Authors:  W R Dunn; T A Hardy; J A Brock
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

8.  Salt intake augments hypotensive effects of transient receptor potential vanilloid 4: functional significance and implication.

Authors:  Feng Gao; Dexin Sui; R Michael Garavito; R Mark Worden; Donna H Wang
Journal:  Hypertension       Date:  2008-12-15       Impact factor: 10.190

9.  Pungent products from garlic activate the sensory ion channel TRPA1.

Authors:  Diana M Bautista; Pouya Movahed; Andrew Hinman; Helena E Axelsson; Olov Sterner; Edward D Högestätt; David Julius; Sven-Eric Jordt; Peter M Zygmunt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

10.  Modulation by nicotinamide adenine dinucleotide of sympathetic and sensory-motor neurotransmission via P1-purinoceptors in the rat mesenteric arterial bed.

Authors:  V Ralevic
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.